New York esophageal squamous cell carcinoma 1 peptide-HLA complex (NY-ESO-1/HLA complex)

The New York esophageal squamous cell carcinoma 1 (NY-ESO-1) peptide-HLA complex is a premier target in cancer immunotherapy, particularly for T-cell receptor (TCR) based interventions. NY-ESO-1 is a cancer-testis antigen encoded by the CTAG1B gene; it is typically expressed only in germ cells and placental tissues which lack MHC Class I molecules, rendering it invisible to the immune system in healthy states (PubMed: 9050856). In various malignancies, such as synovial sarcoma and melanoma, NY-ESO-1 is aberrantly re-expressed and its intracellular proteins are processed into peptides, such as the immunodominant SLLMWITQC fragment, and presented on the cell surface by HLA-A*02:01 (UniProt: P78358). This high tumor specificity makes the complex an ideal target for TCR-engineered T-cells (TCR-T) and bispecific T-cell engagers like ImmTACs, which are designed to recognize the peptide-MHC interface with high affinity (PubMed: 24910252). The clinical utility of this target was recently validated by the FDA approval of Afamitresgene autoleucel, the first TCR-T cell therapy for solid tumors (FDA: 2024). Effective use of therapies targeting this complex requires rigorous patient screening for both the presence of the NY-ESO-1 antigen and the specific HLA restriction element.

Other names

NY-ESO-1/MHC complexCTAG1B peptide-HLA complexNY-ESO-1 pMHCCancer-testis antigen 1B peptide-HLA complexNY-ESO-1/HLA-A*02:01 complex

Engineered T-cell receptor (TCR) recognition of the specific NY-ESO-1 peptide presented by HLA molecules, which triggers T-cell activation, secretion of cytotoxic granules (perforin/granzyme), and targeted lysis of the tumor cell.